Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by BeOne Medicines Ltd.
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
July 31, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
July 28, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
July 16, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
July 10, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
June 26, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
June 25, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
June 12, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
June 11, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
June 11, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
June 02, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
May 31, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
May 27, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright